IL1B and Stroke: For example, in 10,061 patients with previous myocardial infarction and elevated CRP levels, IL-1β-targeted canakinumab (150 mg, every 3 months) treatment (median follow-up time of 3.7 years) significantly reduced recurrence cardiovascular events (HR=0.85) (including non-fatal stroke, non-fatal myocardial infarction, or cardiovascular death), and this action was independent of changes in blood lipid profiles (215).